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Recent advances in mass spectrometry (MS)-based technologies are now
set to transform translational cancer proteomics from an idea to a practice.
Here, we present a robust proteomic workflow for the analysis of clinically
relevant human cancer tissues that allows quantitation of thousands of
tumor proteins in several hours of measuring time and a total turnaround
of a few days. We applied it to a chemorefractory metastatic case of the
extremely rare urachal carcinoma. Quantitative comparison of lung metas-
tases and surrounding tissue revealed several significantly upregulated pro-
teins, among them lysine-specific histone demethylase 1 (LSD1/KDM1A).
LSD1 is an epigenetic regulator and the target of active development
efforts in oncology. Thus, clinical cancer proteomics can rapidly and effi-
ciently identify actionable therapeutic options. While currently described
for a single case study, we envision that it can be applied broadly to other
patients in a similar condition.
1. Introduction
Genomic and transcriptomic investigations based on
next-generation sequencing have revolutionized the
field of oncology in the last decade and allowed the
molecular profiling of thousands of tumors in different
cancer types (Cancer Genome Atlas Research Network
et al., 2013; Stratton et al., 2009). While these tech-
nologies have led to a better understanding of cancer
origin and heterogeneity, it has often been challenging
to turn mutation patterns into actionable therapeutic
suggestions. It has also become evident that the devel-
opment and complexity of cancer cannot be under-
stood at the genetic or transcriptomic level alone.
Clearly, proteins, the driving biological entities in cells,
also play crucial roles in cancer. So far, proteomics—
the large-scale study of all proteins in a given system—
has lagged behind genomics for technological reasons.
Abbreviations
ACACB, acetyl-CoA carboxylase 2; ACOT2, acyl-coenzyme A thioesterase 2; AIFM2, apoptosis-inducing factor 2; CGI, cancer genome
interpreter; COL11A1, collagen alpha-1 (XI) chain; CRP, c-reactive protein; EGFR, epidermal growth factor receptor; FDR, false discovery rate;
FFPE, formalin-fixed paraffin-embedded; FOLFOX, folinic acid, fluorouracil, and oxaliplatin; GSEA, gene set enrichment analysis; HPLC, high-
performance liquid chromatography; iST, inStageTip; LFQ, label-free quantification; LSD1/KDM1A, lysine-specific histone demethylase 1;
MAO, monoamine oxidase; MRI1, methylthioribose-1-phosphate isomerase; MS, mass spectrometry; PC, pyruvate carboxylase; RSU1, ras
suppressor protein 1; SLC22A18, solute carrier family 22 member 18; THBS2, thrombospondin-2; XELOX, oxaliplatin and capecitabine.
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However, following groundbreaking advances in mass
spectrometry (MS)-based proteomics, comprehensive
characterization of nearly complete proteomes has now
become a reality (Aebersold and Mann, 2016; Bekker-
Jensen et al., 2017). In parallel, several proteomic tumor
analysis consortia (e.g. CPTAC) have been launched
and aim to systematically identify and characterize can-
cer-relevant proteins. So far, these consortia have
focused on knowledge generation, rather than on speci-
fic clinical applications.
Here, we set out to use state-of-the-art proteomics
technology directly in a clinical oncology context, as
the main focus of this work. Our group has already
established proteomic workflows enabling processing
of clinically relevant tissue samples to great depth,
even for formalin-fixed paraffin-embedded (FFPE)
material (Wisniewski et al., 2011, 2013). Recently, we
have combined nearly all sample processing steps in a
single reaction tube, thereby reducing preparation
time, contamination, and loss, while increasing quan-
tification accuracy in tissues (inStageTip or iST
method) (Kulak et al., 2014; Doll et al., 2017). We
reasoned that these advances would now enable rapid
analysis of individual tumor tissues to inform treat-
ment decisions, especially in patients with rare and
end-stage cancer, where evidence for therapeutic strate-
gies and clinical trials are often lacking.
Urachal carcinomas originate from a remnant of the
fetal structure connecting the allantois and the blad-
der. This form of cancer is rare, accounting for less
than 1% of all bladder cancers, aggressive, and conse-
quently little studied. Patients with metastatic urachal
cancer have very poor prognosis, with median survival
of about 1.3 years. Currently, there are no standard
chemotherapeutic regimens for metastatic urachal car-
cinomas, as prospective clinical trials are hampered by
its rarity (Molina et al., 2007; Szarvas et al., 2016).
Only a few cases have been investigated at the genomic
level (Collazo-Lorduy et al., 2016; Singh et al., 2016),
and there are no global protein expression profiles of
urachal carcinoma that could support the search for
biomarkers, therapeutic targets, or disease signatures.
A 57-year-old woman presented with a progressive
pulmonary metastasis of a recurrent metastatic urachal
carcinoma after multimodality treatment including sur-
gery, chemotherapy regimens, and radiation therapy.
The patient wished to continue treatment with no fur-
ther systemic treatments currently available. Based on
the iST sample preparation method, we developed a
workflow capable of producing analysis results of clini-
cal cancer tissues in only about two days. Profiling the
proteomic landscape of the metastasized tumor in
comparison with the normal appearing surrounding
tissue, we aimed to uncover potential therapeutic tar-
gets and gain a deeper understanding of the molecular
mechanisms underlying this disease and its progres-
sion. We also employed proteomics to characterize the
archived primary tumor and compared our results to
deep sequencing data that we obtained from the same
metastases.
2. Results
2.1. Prior clinical course
Initially, our patient was referred to the Department
of Urology at the University Medical Center Man-
nheim in 2013. Early symptoms included gross hema-
turia, which led us to perform a subsequent cystoscopy
and bladder biopsy. Histopathology revealed a muci-
nous adenocarcinoma in the bladder, a finding consis-
tent with a diagnosis of urachal carcinoma. As a first
line of treatment, we performed a partial cystectomy
and lymphadenectomy. Our final pathology showed a
pT3b, pN1, L1, V1, R0 mucinous urachal carcinoma
of the bladder (Fig. S1A). Follow-up CT scans were
performed on a 3-month basis. Nine months after
resection, the CT scan revealed two suspicious hypo-
dense lesions in the liver (segments 5 and 4a) as well
as a local recurrence found at the bladder dome
(Fig. S1B,C). The local tumor board recommended
chemotherapy, including one cycle of XELOX (oxali-
platin and capecitabine) and nine cycles of FOLFOX
(folinic acid, fluorouracil, and oxaliplatin). Chemother-
apy led to a partial hepatic response but was stopped
due to severe peripheral neuropathy. To assess further
treatment strategies, the local recurrence was biopsied
and confirmed transurethrally. After tumor board con-
sultation, we performed a resection of the local recur-
rence combined with a partial hepatectomy and
subsequent radiotherapy of the local recurrence side
(59.4 Gy). In later stages, two metastases were diag-
nosed at the introitus vaginae and the CT scan of the
thorax revealed bilateral noduli. Subsequent
chemotherapy with four cycles of gemcitabine/cisplatin
led to a mixed response, and further pulmonary pro-
gression of a predominant singular nodule was diag-
nosed (Fig. 1A). At this point, all standard treatment
options were exhausted and we set out to resect the
lung metastasis and surrounding healthy tissue for sub-
sequent proteomic analyses. Due to medical and psy-
chological issues, the resection was delayed for two
months. In the thoracoscopy, a disseminated pleural
carcinosis was observed that was most likely covered
by pleural effusion in the preoperative CT scan
(Fig. 1B). Pleural metastases and healthy pleura were
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biopsied, washed in PBS, flash-frozen, and immediately
transferred for proteomic analyses within 1 day.
2.2. Streamlined proteomics workflow applied to
chemorefractory carcinoma
To be useful in a clinical oncology setting, we reasoned
that any proteomic workflow would need to fulfill sev-
eral criteria, including rapid overall analysis time (few
days), extreme sensitivity (few thousand cells), depth of
quantitative proteome coverage (several thousand pro-
teins) along with robustness and reproducibility. The
workflow that we adapted fulfills all these criteria (see
Methods section for details): Briefly, we performed all
sample preparation in a single reaction vial, based on
the iST sample preparation method (Kulak et al.,
2014). We chose a single-run LC-MS/MS workflow,
rather than prefractionating the sample, to minimize
measurement time and maximize quantitative accuracy.
All bioinformatic analysis was done in the freely avail-
able MAXQUANT and PERSEUS software environments
(Cox and Mann, 2008; Tyanova et al., 2016).
Upon receipt of the samples in the late afternoon, we
started by lysing the tissues and extracting the proteins.
The surrounding fat was removed by high-speed cen-
trifugation. Proteins were subsequently digested over-
night using specific proteases. On the following day, we
analyzed the peptide mixtures using a state-of-the-art
label-free workflow on a quadrupole—Orbitrap mass
spectrometer (Fig. 2B). Each sample, constituting a few
microgram of material, was measured using 100-min
high-performance liquid chromatography (HPLC) gra-
dients. Analysis in MaxQuant specified a false discov-
ery rate (FDR) of less than 1% at the peptide and
protein levels. In total, we identified 50 870 sequence-
unique peptides, corresponding to 5562 protein groups
(proteins that can be distinguished based on the avail-
able peptide information). The MaxLFQ algorithm
(Cox et al., 2014) quantified 5543 proteins in total, with
similar coverage in all samples. For further analysis, we
only considered the subset of 4857 proteins in our data
with quantitative valid values across at least 70% of
the samples. Mean sequence coverage of all proteins by
identified peptides was about 25%. Signal intensities
for the quantified proteins spanned about five orders of
magnitudes, with hemoglobin as one of the most abun-
dant proteins, despite extensive washing of the samples
with PBS before sample processing. Quantitative repro-
ducibility between technical replicates (same tissue ori-
gin but independent analysis workflow) was excellent,
demonstrated by Pearson correlation coefficients
between 0.97 and 0.99 that are similar to previously
achieved values in cell line systems (Coscia et al.,
2016). We likewise observed high correlation values
between control tissues taken from different locations
(0.92) and between two different samplings of the
March 2017 June 2017
Pleural
effusion
Lung
Main metastasis
Liver
A B
Fig. 1. Preoperative CT scans of the urachal carcinoma patient. (A) CT scan in March 2017 showing a metastasis in the right lung.
(B) CT scan in June 2017 depicting a pleural effusion before the surgery hiding a pleural carcinosis
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metastases (0.97). The complete workflow can be per-
formed in less than 2.5 days, which is an important
advantage for application in the clinic.
2.3. Proteome analysis reveals LSD1 as a
potential therapeutic target
For a functional view of the proteomic data, we used
volcano plots to compare expression differences
between lung pleural metastases and healthy-appearing
pleura. Based on a t-test for binary comparison and
employing a 5% FDR, we found that 108 (2.2%) pro-
teins showed significant alteration, of which 47 were
up- and 61 downregulated in the metastases. Gene set
enrichment analysis (GSEA) using gene set collections
from the MSigDB (Subramanian et al., 2005) revealed
that proteins upregulated in the metastases were
significantly enriched for the terms epithelial-
mesenchymal transition, tumor invasiveness, and
tumor metastasis (P < 5 9 106). For example, perios-
tin (POSTN), which has previously been reported to
promote cell motility in several cancer types, was 13-
fold higher expressed in the metastases compared to
nondiseased tissue (Gillan et al., 2002; Ishiba et al.,
2014; Mikheev et al., 2015). The most upregulated
(>100-fold) protein in the metastases was throm-
bospondin-2 (THBS2) and is also involved in cell
invasion as well as angiogenesis and correlates with
poor survival (Bornstein, 2009; Iruela-Arispe et al.,
2004; Lin et al., 2016; Qian et al., 2017; Wang et al.,
2016). Another protein driving cell invasion, methylth-
ioribose-1-phosphate isomerase (MRI1) was highly
significantly upregulated but only 1.9-fold (Kabuyama
et al., 2009). These observations demonstrate that the
proteomic experiment performed as expected and sug-
gest an important role of some of the regulated
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Fig. 2. Proteomics workflow for the case study. (A) Timeline of the project. (B) Experimental design, including source of material,
inStageTip sample preparation, and depiction of the analytical workflow.
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proteins in the metastatic progression of urachal carci-
noma.
In contrast, downregulated proteins were signifi-
cantly enriched in mitochondrial proteins (P < 1017),
such as pyruvate carboxylase (PC), acetyl-CoA car-
boxylase 2 (ACACB), and acyl-coenzyme A thioester-
ase 2 (ACOT2). Interestingly, Ras suppressor protein
1 (RSU1) was about fourfold lower expressed in the
metastases. Apoptosis-inducing factor 2 (AIFM2) was
28-fold downregulated in the metastases compared
with nondiseased tissue. This suggests a regulatory
role of RSU1 and AIFM2 in urachal carcinoma
metastases.
In an effort to derive therapeutic options, we first
reduced the total number of significantly upregulated
proteins by applying a more stringent cutoff (1%
FDR). This yielded four significantly upregulated pro-
teins in the metastatic tissue: MRI1, solute carrier fam-
ily 22 member 18 (SLC22A18), collagen alpha-1 (XI)
chain (COL11A1), and lysine-specific histone demethy-
lase 1A (KDM1A, also known as LSD1) (Fig. 3A).
Next, we asked which of these proteins were poten-
tially druggable, which left us with LSD1 as the sole
remaining candidate. We quantified LSD1 with 11
unique peptides, reaching an approximate sequence
coverage of 20%, and found that it was 16-fold more
highly expressed in the metastases compared to the
control.
LSD1 is an epigenetic regulator that demethylates
both the activating histone mark H3K4me and the
repressive mark H3K9me, thereby acting as a coactiva-
tor or corepressor, depending on cellular context.
LSD1 has previously been reported as upregulated in
multiple cancer types and its inhibition has antitumor
activity in lung cancer (Mohammad and Kruger, 2016;
Singh et al., 2015). These findings led to the develop-
ment of multiple LSD1 inhibitors that are currently in
clinical trials (Alsaqer et al., 2017; Mohammad and
Kruger, 2016; Schmidt and McCafferty, 2007). Even
though it was unclear whether the lung metastases
would respond to an LSD1 inhibitor, there were no
other rational or reasonable treatment options avail-
able at this point. However, extensive efforts to obtain
one of these drugs for use in our patient ultimately
proved unsuccessful. Fortunately, tranylcypromine a
drug developed decades ago and FDA approved for
the treatment of depression and anxiety (Burger and
Yost, 1948) has recently been shown to irreversibly
inhibit LSD1 as a side effect (Binda et al., 2010; Ulrich
et al., 2017; Zheng et al., 2016). This analogue of
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Fig. 3. Proteins differentially expressed in the urachal carcinoma lung metastases. (A) Volcano plot of the p-values (y-axis) vs. the log2
protein abundance differences (x-axis) between metastases and control, with lines of significance colored in black or gray lines
corresponding to a 5% or 1% FDR, respectively. (B) Mechanisms of action of LSD1/KDM1A.
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amphetamine is a monoamine oxidase (MAO) inhibi-
tor, an enzyme family that is mechanistically related to
LSD1. Tranylcypromine and derivates of this drug
already showed clinical efficacy for several conditions
in clinical trials, including the treatment of acute mye-
loid leukemia. The local tumor board approved treat-
ment with this drug, and our patient was prescribed a
tyramine-free diet, to prevent accumulation of tyra-
mine (normally metabolized by MAO), which could
lead to high blood pressure and culminate in a hyper-
tensive crisis (Gillman, 2011; Ulrich et al., 2017). How-
ever, a baseline CT at the initiation of therapy
revealed dramatic metastatic progression to the liver,
concurrent with hepatic failure (Fig. S1D). The patient
was then transferred to a palliative care ward and died
soon after.
Mass spectrometry-based proteomics is a multi-
faceted technology and further allowed us to investi-
gate the plasma proteome of our patient. Based on
our previously developed ‘plasma proteome profiling’
pipeline (Geyer et al., 2016a), we quantified more than
400 proteins in triplicate LC-MS measurements,
enabling quantification of inflammatory proteins, such
as C-reactive protein (CRP) and the majority of the
complement system (Fig. S2). We identified the entire
inflammatory panel which we have previously reported
and found it to be clearly elevated compared to nor-
mal controls with CRP showing the strongest upregu-
lation (>6-fold) (Geyer et al., 2016b), reflecting the
systemic inflammation commonly observed in patients
with end-stage malignancy and heavy metastatic load.
We also investigated whether the patient would be
likely to respond to immunotherapy. MS-based mea-
surements did not reveal any expression of PD-1 or
PD-L1 proteins, an observation that was later con-
firmed by immunohistochemistry, suggesting a poor
response to immunotherapy-based treatments
(Fig. S3C,D). In addition, we did not observe any
immune cell infiltration in the metastases.
2.4. Proteomic analysis of the primary tumor
To further investigate the proteomic landscape of our
quantitative and in-depth proteomic case study, we
next analyzed the primary tumor, which had been pre-
served as FFPE material for several years. H&E stain-
ing showed that it was rich in extracellular mucin and
stroma compared to healthy control tissue (Fig. 4B,C).
Our proteomic analysis revealed major differences
between the primary and healthy surrounding tissue
(Fig. 4A). In total, we quantified approximately 4200
proteins and found that mucinous (e.g. MUC1 and
MUC2) and mesenchymal proteins (such as THBS2,
COL11A1, and CTHRC1) were significantly upregu-
lated in the primary tumor compared to healthy sur-
rounding tissue. Generally, the epithelial-mesenchymal
transition and thus mesenchymal gene upregulation
are associated with poor prognosis in various malig-
nancies including colorectal cancer and ovarian cancer
(Chen et al., 2014; Rokavec et al., 2017; Sleeman and
Thiery, 2011). The fact that mesenchymal proteins
were highly enriched in the primary tumor is concor-
dant with the later development of multiple and
aggressive metastases. Interestingly, we also found that
LSD1 appeared to be upregulated in the metastases
compared to the primary tumor, albeit not signifi-
cantly.
2.5. Next-generation sequencing analysis of the
metastases
To gain additional insights into the overall molecular
mechanisms underlying urachal carcinoma, tumor eti-
ology and to compare transcriptomics to proteomics,
we also extracted RNA and DNA for subsequent
next-generation sequencing. The quality of the
extracted RNA from the metastatic samples, however,
was poor prohibiting direct transcriptomic analysis,
which would have required additional steps in RNA
stabilization. In contrast, we were able to isolate DNA
of high quality, allowing us to perform exome
sequencing on our samples. Comparing metastatic and
surrounding tissues, we observed hundreds of muta-
tions in coding regions, indicating a hypermutated
phenotype, consistent with a previous report on ura-
chal carcinoma (Kardos et al., 2017). Data were fur-
ther filtered resulting in 320 high-confidence somatic
point mutations, including 83 exonic mutations (Meth-
ods and Table S1). In order to interpret the relevance
of these mutations and also study the possible anti-
cancer therapies, we further analyzed them using the
cancer genome interpreter (CGI) (Tamborero et al.,
2018). This tool helped us to annotate the tumorigenic
potential of the called variants as well as to identify
the alterations that could be therapeutically targeted
and the observed response. CGI catalogue identified
five proteins affecting driver mutations (one known
mutation in COREAD: K117N in exon 4 of KRAS,
and four predicted driver mutations [oncodriveMUT
(Tamborero Noguera et al., 2016) E566V (MCC),
D1046A (KDR), Y641C (FN1) and Q167 (TP53)].
Mutations in members of the EGFR pathway, includ-
ing KRAS, are of particular interest as the use of
EGFR inhibitors such as gefitinib has been described
for urachal carcinoma recently (Collazo-Lorduy et al.,
2016; Singh et al., 2016; Sirintrapun et al., 2014).
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Unfortunately, several studies reported that patients
with KRAS mutations in exons 2, 3, and 4 did not
respond to EGFR-targeted therapy (Bokemeyer et al.,
2015; Douillard et al., 2013). We also found two intro-
nic and two exonic somatic mutations of the LSD1
gene, which, however, scored neutral by mutation
effect predictors (Fig. S4).
3. Discussion
Modern oncology is at a turning point where systemic
cancer treatment is moving toward more personalized
approaches based on molecular characterization of
each individual’s tumor (Schork, 2015). This is particu-
larly promising for patients suffering from rare cancers,
where standard chemotherapies often fail and large
clinical studies are unlikely to be performed. In the
near future, sequencing at the genomic, transcriptomic
and proteomic levels might provide the basis for
individual targeted treatment prescription and thereby
change clinical practice. However, while genomics will
always be the gold standard for identifying genome
alteration in cancer, the spectrum of mutations by itself
does not necessarily lead to clear therapeutic options, a
problem that becomes even more acute when consider-
ing mutational heterogeneity of most tumors. These
general challenges are well known and were reflected in
our case study, where mutational analysis did not lead to
a clear treatment recommendation. In contrast, our per-
sonalized MS-based proteomic analysis performed
robustly and quickly on both the lung metastases and the
archived primary tumor. The significance of our study is
its demonstration that proteomics has the potential to
provide personalized therapeutic options for patients
where standard clinical options have been exhausted.
The current standard treatment for localized urachal
cancer is surgery, whereas chemotherapy is used in
metastatic disease. Given the rarity of this cancer type,
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robust data from prospective trials on chemotherapy
regimens are unlikely to be obtainable and evidence
mainly consists of small retrospective cohorts. Due to
the similarity of urachal cancer to colorectal adenocar-
cinoma and urothelial carcinomas, treatment regimens
are generally extrapolated from these diseases, justify-
ing the FOLFOX therapy prescribed to our patient.
Targeted EGFR inhibitors (e.g. gefitinib) have been
used for urachal carcinoma recently. To guide decisions
concerning this alternative therapy option, we further
looked into KRAS mutations and uncovered a mis-
sense mutation. However, EGFR-targeted therapy was
not initiated because patients with similar KRAS muta-
tions as our patient did not respond to therapy (Boke-
meyer et al., 2015; Douillard et al., 2013).
Furthermore, the elevated liver enzymes of our patients
were contraindications for such a therapy. In the search
for possible further treatment options in this patient,
we found that PD-L1 and CD8 immunohistochemistry
were also negative, suggesting a poor response to
checkpoint inhibitors.
Lacking evidence-based treatment options for our
end-stage patient, who was willing to exhaust all possi-
bilities, we turned to MS-based proteomic analysis,
which identified LSD1 as a therapeutic target highly
enriched in metastatic tissue. This promising treatment
opportunity provided timely and actionable results to
the patient and the clinicians. Of note, the proteomic
sample preparation and data analysis were accom-
plished in only about 2 days, much faster than the
genomic analysis. This highlights the promise of MS-
based proteomics in clinical routine, where fast target
identification for cancer patients beyond standard
treatment could be highly beneficial.
4. Conclusion
In summary, we demonstrated that fast and repro-
ducible proteomics can create the possibility for clini-
cians to use proteomics for personalized diagnosis and
treatment in the clinical setting. By combining genomic
with proteomic data, we further informed therapeutic
decisions. We aim to apply this workflow to cancer
patients in a variety of chemorefractive tumors, in the
hope of identifying additional treatment options for at
least some of them.
5. Materials and methods
5.1. Sample preparation
Lung metastases were collected during surgery from
the pleural cavity (pleura parietalis) and compared to
surrounding noncancerous pleura tissue. In total, we
analyzed six metastatic and six ‘control’ samples that
originated from two metastases and surrounding tissue
collected at different locations of the pleural cavity.
Samples were washed three times with cold PBS before
flash-freezing the samples in liquid nitrogen and ship-
ping on dry ice. The samples were split to enable geno-
mic and proteomic analysis. The archived primary
tumor was surrounded with healthy bladder tissue and
preserved as FFPE material. The investigation was
approved by the local ethical committee (2015-540-
MA), and the experiments were undertaken with the
understanding and written consent of the patient. The
study methodologies conformed to the standards set
by the Declaration of Helsinki.
5.1.1. Proteomic sample preparation
Control and lung metastases samples were thawed on
ice and prepared following the in stage tip sample
preparation method with minor modifications (Kulak
et al., 2014). Briefly, 100 lL of the reducing alkylating
sodium deoxycholate buffer (PreOmics, Martinsried,
Germany) was added to the samples before protein
denaturation at 100 °C for 20 min. Samples were fur-
ther homogenized by 15-min sonication in a Biorupter
(30 s on/off cycles, high settings). Proteins were then
digested by Lys-C and trypsin overnight at 37 °C and
constant agitation. Peptides were acidified to a final
concentration of 0.1% trifluoroacetic acid (TFA) for
SDB–RPS binding and desalted before LC-MS/MS
analysis.
5.1.2. Exome sequencing
DNA was extracted from tissues using the DNeasy
Blood & Tissue Kit (Qiagen, Hamburg, Germany)
according to the manufacturer’s instruction. DNA
quality was controlled by measurement of the 260/
280 nm ratio using a NanoDrop photospectrometer
and Exome Seq Libraries prepared from 100 ng of
genomic DNA using the TruSeq Exome Library Prep
Kit from Illumina. Briefly, the DNA was fragmented
using a Covaris M220 and ligated to Illumina adap-
ters. Exonic oligo probes were used to hybridize the
coding exons and subsequently captured for enrich-
ment of those targeted coding regions. The hybridiza-
tion was performed overnight twice to ensure high
specificity of the captured regions. The final libraries
were checked on the Fragment Analyzer (AATI) and
quantified by qPCR with KAPA Library Quantifica-
tion Kit (Kapa Biosystems, Roche, Basel, Switzer-
land). Sequencing was performed with the Illumina
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NextSeq 500 using a mid-output flowcell and a paired-
end mode 2x75 cycles, reaching 45 million reads per
sample. The resulting reads for the tumor and normal
samples were aligned to the hg19 reference genome
with BWA (Li and Durbin, 2009) and afterward pro-
cessed according to the GATK Best Practices recom-
mendations for variant discovery (DePristo et al.,
2011; McKenna et al., 2010; Van der Auwera et al.,
2013). The discovered variant callset was then filtered
and annotated using MuTect (Cibulskis et al., 2013),
which allows identification of somatic point mutations
with high confidence. We further interpreted the rele-
vance of these mutations and possible anticancer ther-
apies using the cancer genome interpreter (CGI)
(Tamborero et al., 2018).
5.2. Liquid chromatography–MS analysis
Samples were measured on a quadrupole Orbitrap
mass spectrometer (Kelstrup et al., 2014; Scheltema
et al., 2014) (Q Exactive HF, Thermo Fisher Scientific,
Rockford, IL, USA) coupled to an EASYnLC 1200
ultra-high-pressure system (Thermo Fisher Scientific)
via a nanoelectrospray ion source. About 1 lg of pep-
tides was loaded on a 40-cm HPLC-column (75 lm
inner diameter; in-house packed using ReproSil-Pur
C18-AQ 1.9-lm silica beads; Dr Maisch GmbH, Ger-
many). Peptides were separated using a linear gradient
from 3% to 23% B in 82 min and stepped up to 40%
in 8 min at 350 nL per min where solvent A was 0.1%
formic acid in water and solvent B was 80% acetoni-
trile and 0.1% formic acid in water. The total duration
of the gradient was 100 min. Column temperature was
kept at 60 °C by a Peltier element-containing, in-house
developed oven. The mass spectrometer was operated
in ‘top-15’ data-dependent mode, collecting MS spec-
tra in the Orbitrap mass analyzer (60 000 resolution,
300–1650 m/z range) with an automatic gain control
(AGC) target of 3E6 and a maximum ion injection
time of 25 ms. The most intense ions from the full
scan were isolated with a width of 1.4 m/z. Following
higher-energy collisional dissociation (HCD) with a
normalized collision energy (NCE) of 27%, MS/MS
spectra were collected in the Orbitrap (15 000 resolu-
tion) with an AGC target of 1E5 and a maximum ion
injection time of 25 ms. Precursor dynamic exclusion
was enabled with a duration of 20 s.
5.3. MS data analysis
Tandem mass spectra were searched against the 2015
Uniprot human databases (UP000005640_9606 and
UP000005640_9606_additional) using MAXQUANT version
1.5.3.34 with a 1% FDR at the peptide and protein level,
peptides with a minimum length of seven amino acids
with carbamidomethylation as a fixed modification and
protein N-terminal acetylation and methionine oxida-
tions as variable modifications (Cox and Mann, 2008).
Enzyme specificity was set as C-terminal to arginine and
lysine using trypsin as protease, and a maximum of two
missed cleavages were allowed in the database search.
The maximum initial mass tolerance for precursor and
fragment ions was 4.5 ppm and 20 ppm, respectively. If
applicable, peptide identifications by MS/MS were trans-
ferred between runs to minimize missing values for quan-
tification with a 0.7 min window after retention time
alignment. Label-free quantification was performed with
the MaxLFQ algorithm using a minimum ratio count of
1. All MS proteomic data have been deposited on Pro-
teomeXchange via the PRIDE database with the data set
identifier PXD008713.
5.4. Statistical analysis
Statistical and bioinformatics analysis was performed
with the PERSEUS software (Tyanova et al., 2016) (ver-
sion 1.5.5.0), Microsoft Excel, and R statistical soft-
ware. Proteins that were identified in the decoy reverse
database or only by site modification were not consid-
ered for data analysis. Median of technical triplicates
(referring to independent sample preparations) were
calculated and mean log2 ratios of biological dupli-
cates (two metastases and two control tissues collected
at different locations of the pleural cavity), and the
corresponding p-values were visualized with volcano
plots. We used t-tests for binary comparisons and
SAM with s0 = 0.1 and a FDR < 0.05 or <0.01 for the
assessment of t-test results in volcano plots. The FDR
was corrected for multiple hypotheses based on permu-
tation-based FDR correction.
5.5. Histology and Immunohistochemistry
Tissue samples were fixed in 4% buffered formaldehyde,
paraffin-embedded, cut at 4 lm, and subjected to routine
staining procedures including hematoxylin and eosin
stain (H&E). Immunohistochemistry was performed
using PD-L1 monoclonal antibody clone E1L3N (Cell
Signaling Technology, Frankfurt am Main, Germany)
and diaminobenzidine (DAB) substrate chromogen
detection system (Dako, Hamburg, Germany).
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